Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition.

Pieterse E, Rother N, Garsen M, Hofstra JM, Satchell SC, Hoffmann M, Loeven MA, Knaapen HK, van der Heijden OWH, Berden JHM, Hilbrands LB, van der Vlag J.

Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1371-1379. doi: 10.1161/ATVBAHA.117.309002. Epub 2017 May 11.

PMID:
28495931
2.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

3.

Pharmacological treatment of primary membranous nephropathy in 2016.

van de Logt AE, Hofstra JM, Wetzels JF.

Expert Rev Clin Pharmacol. 2016 Nov;9(11):1463-1478. doi: 10.1080/17512433.2016.1225497. Epub 2016 Sep 16. Review.

PMID:
27535699
4.

Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?

Hofstra JM, Wetzels JFM.

Kidney Int. 2016 May;89(5):981-983. doi: 10.1016/j.kint.2016.01.019.

PMID:
27083274
5.

Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.

van de Logt AE, Beerenhout CH, Brink HS, van de Kerkhof JJ, Wetzels JF, Hofstra JM.

PLoS One. 2015 Nov 12;10(11):e0142033. doi: 10.1371/journal.pone.0142033. eCollection 2015.

6.

Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.

van de Logt AE, Hofstra JM, Wetzels JF.

Kidney Int. 2015 Jun;87(6):1263-4. doi: 10.1038/ki.2015.34. No abstract available.

PMID:
26024039
7.

Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy.

Maas RJ, van den Brand JA, Waanders F, Meijer E, Goor van H, Peters HP, Hofstra JM, Wetzels JF.

Ann Clin Biochem. 2016 Jan;53(Pt 1):51-7. doi: 10.1177/0004563215579694. Epub 2015 Mar 11.

PMID:
25762211
8.

Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.

Bech AP, Hofstra JM, Brenchley PE, Wetzels JF.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1386-92. doi: 10.2215/CJN.10471013. Epub 2014 Jul 17.

9.

TRPC6 single nucleotide polymorphisms and progression of idiopathic membranous nephropathy.

Hofstra JM, Coenen MJ, Schijvenaars MM, Berden JH, van der Vlag J, Hoefsloot LH, Knoers NV, Wetzels JF, Nijenhuis T.

PLoS One. 2014 Jul 14;9(7):e102065. doi: 10.1371/journal.pone.0102065. eCollection 2014.

10.

Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1066-73. doi: 10.2215/CJN.08880813. Epub 2014 May 22.

11.

Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.

Hofstra JM, Wetzels JF.

J Am Soc Nephrol. 2014 Jun;25(6):1137-9. doi: 10.1681/ASN.2014010091. Epub 2014 Mar 7. No abstract available.

12.

B cell suppression in primary glomerular disease.

Rood IM, Hofstra JM, Deegens JK, Wetzels JF.

Adv Chronic Kidney Dis. 2014 Mar;21(2):166-81. doi: 10.1053/j.ackd.2014.01.005. Review.

PMID:
24602466
13.

Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF.

J Am Soc Nephrol. 2014 Jan;25(1):150-8. doi: 10.1681/ASN.2013020185. Epub 2013 Sep 12.

14.

Treatment of idiopathic membranous nephropathy.

Hofstra JM, Fervenza FC, Wetzels JF.

Nat Rev Nephrol. 2013 Aug;9(8):443-58. doi: 10.1038/nrneph.2013.125. Epub 2013 Jul 2. Review.

PMID:
23820815
15.

Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.

Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W.

Clin Chim Acta. 2013 Jun 5;421:213-8. doi: 10.1016/j.cca.2013.03.015. Epub 2013 Mar 27.

PMID:
23541686
16.

Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P.

J Am Soc Nephrol. 2013 Mar;24(4):677-83. doi: 10.1681/ASN.2012070730. Epub 2013 Feb 21.

17.

New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis.

Hofstra JM, Lainez S, van Kuijk WH, Schoots J, Baltissen MP, Hoefsloot LH, Knoers NV, Berden JH, Bindels RJ, van der Vlag J, Hoenderop JG, Wetzels JF, Nijenhuis T.

Nephrol Dial Transplant. 2013 Jul;28(7):1830-8. doi: 10.1093/ndt/gfs572. Epub 2013 Jan 4.

PMID:
23291369
18.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF.

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. Epub 2012 Sep 6.

19.

An overview of immunosuppressive therapy in idiopathic membranous nephropathy.

Maas R, Hofstra JM, Wetzels JF.

Minerva Med. 2012 Aug;103(4):253-66. Review.

PMID:
22805618
20.

Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

van den Brand JA, Hofstra JM, Wetzels JF.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1242-8. doi: 10.2215/CJN.00670112. Epub 2012 May 17.

21.

Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

Hofstra JM, Wetzels JF.

Neth J Med. 2012 Apr;70(3):109-13. Review.

22.

Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.

van den Brand JA, Hofstra JM, Wetzels JF.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2846-53. doi: 10.2215/CJN.04020411.

23.

Management of patients with membranous nephropathy.

Hofstra JM, Wetzels JF.

Nephrol Dial Transplant. 2012 Jan;27(1):6-9. doi: 10.1093/ndt/gfr371. Epub 2011 Jul 7. No abstract available.

PMID:
21737514
24.

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.

25.

Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.

Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R.

N Engl J Med. 2011 Feb 17;364(7):616-26. doi: 10.1056/NEJMoa1009742.

26.

Estimated glomerular filtration rate in the nephrotic syndrome.

Hofstra JM, Willems JL, Wetzels JF.

Nephrol Dial Transplant. 2011 Feb;26(2):550-6. doi: 10.1093/ndt/gfq443. Epub 2010 Jul 25.

PMID:
20660475
27.

Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.

Hofstra JM, Wetzels JF.

Nephrol Dial Transplant. 2010 Jun;25(6):1760-6. doi: 10.1093/ndt/gfq017. Epub 2010 Feb 3. Review. No abstract available.

PMID:
20133280
28.

Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.

Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF.

Nephrol Dial Transplant. 2010 Jan;25(1):129-36. doi: 10.1093/ndt/gfp390. Epub 2009 Aug 8.

PMID:
19666912
29.

Cystatin C levels are unaltered in patients with diabetes mellitus and normal renal function.

Hofstra JM, Vervoort G, Willems JL, Wetzels JF.

Kidney Int. 2009 Aug;76(4):462. doi: 10.1038/ki.2009.167. No abstract available.

30.
31.

Urinary albumin: total protein ratio--a new diagnostic tool to differentiate glomerular from nonglomerular hematuria.

Hofstra JM, Wetzels JF.

Nat Clin Pract Nephrol. 2008 Nov;4(11):590-1. doi: 10.1038/ncpneph0942. Epub 2008 Sep 9. No abstract available.

PMID:
18779852
32.

Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.

Hofstra JM, Wetzels JF.

Nephrol Dial Transplant. 2008 Nov;23(11):3534-8. doi: 10.1093/ndt/gfn350. Epub 2008 Jun 17.

PMID:
18559961
33.

Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.

Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF.

Nephrol Dial Transplant. 2008 Oct;23(10):3160-5. doi: 10.1093/ndt/gfn190. Epub 2008 Apr 10.

PMID:
18403431
34.

Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.

Hofstra JM, Deegens JK, Willems HL, Wetzels JF.

Nephrol Dial Transplant. 2008 Aug;23(8):2546-51. doi: 10.1093/ndt/gfn007. Epub 2008 Feb 28.

PMID:
18308774
35.

Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?

Hofstra JM, Deegens JK, Wetzels JF.

Nephrol Dial Transplant. 2007 Jul;22(7):2100-2. Epub 2007 Mar 26. No abstract available.

PMID:
17389619

Supplemental Content

Loading ...
Support Center